PubRank
Search
About
Christine Mateus
Author PubWeight™ 47.45
‹?›
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
N Engl J Med
2013
18.08
2
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
N Engl J Med
2015
8.64
3
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.
J Clin Oncol
2009
2.16
4
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network.
PLoS One
2013
2.01
5
RAF inhibition and induction of cutaneous squamous cell carcinoma.
Curr Opin Oncol
2011
1.92
6
Hemophilia A induced by ipilimumab.
N Engl J Med
2011
1.55
7
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.
Clin Cancer Res
2011
1.52
8
[Anti-CTLA-4 monoclonal antibody: a major step in the treatment of metastatic melanoma].
Med Sci (Paris)
2011
1.38
9
Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?
Clin Cancer Res
2008
1.21
10
Rituximab therapy for HIV-associated Castleman disease.
Blood
2003
1.16
11
Kidney injuries related to ipilimumab.
Invest New Drugs
2014
1.03
12
Vemurafenib and radiosensitization.
JAMA Dermatol
2013
0.95
13
A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib.
Arch Dermatol
2012
0.94
14
Melanomas Associated With Blue Nevi or Mimicking Cellular Blue Nevi: Clinical, Pathologic, and Molecular Study of 11 Cases Displaying a High Frequency of GNA11 Mutations, BAP1 Expression Loss, and a Predilection for the Scalp.
Am J Surg Pathol
2016
0.86
15
Mycosis fungoides-type cutaneous T-cell lymphoma and neutrophilic dermatosis.
Arch Dermatol
2005
0.86
16
Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggering.
Cancer Res
2013
0.84
17
Severe meningo-radiculo-neuritis associated with ipilimumab.
Invest New Drugs
2012
0.82
18
The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma.
Br J Cancer
2008
0.81
19
Defining the clinical condition of cancer patients: it is time to switch from performance status to nutritional status.
Support Care Cancer
2011
0.79
20
[Screening and early diagnosis of other cancers (non-small cell lung carcinoma, urologic cancers, liver cancer and melanoma)].
Rev Prat
2010
0.78
21
Advances in the management of cutaneous toxicities of targeted therapies.
Semin Oncol
2012
0.78
22
Correlation of phenotype/genotype in a cohort of 23 xeroderma pigmentosum-variant patients reveals 12 new disease-causing POLH mutations.
Hum Mutat
2014
0.78
23
Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
Cell Res
2015
0.77
24
[Cutaneous effects related to the use of tyrosine kinase inhibitors].
Rev Pneumol Clin
2007
0.75
25
Scurvy in liver transplant patients.
J Am Acad Dermatol
2006
0.75
26
Melanoma arising from a long-standing pigmented trichoblastoma: clinicopathologic study with complementary aCGH/mutational analysis.
Am J Dermatopathol
2014
0.75
27
Acute Lower Limb Ischaemia and Diabetes in a Patient Treated with Anti-PD1 Monoclonal Antibody for Metastatic Melanoma.
Acta Derm Venereol
2017
0.75